Trial
NCT03062319
Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
Phase IVTERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
National Hospital Organization Osaka National Hospital
Collaborators
Network for Clinical Stroke Trials; The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program
Condition
Ischemic Stroke
Intervention
Oral Anticoagulant
Why stopped
The trial was terminated at the planned interim analysis for futility on July 18, 2023.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-27